{
  "retracted": false,
  "timestamp": 1573776000000,
  "updates": [
    {
      "timestamp": 1573785697847,
      "identifier": {
        "doi": "10.1007/s40273-019-00857-7"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s40273-019-00829-x"
  },
  "journal": "PharmacoEconomics",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA"
}
